ETF Growth Opportunities in Chinese Biotech

The video discusses a niche Chinese biotech ETF, comparing it with another healthcare ETF, CHIH. It highlights the emerging biotech sector in China, supported by government reforms and returning entrepreneurs. The impact of US-China trade relations on biotech is explored, noting that tariffs on medicines are unlikely. The video also covers trends in immunotherapy, with recent market challenges and future prospects. Finally, it discusses Hong Kong's new rules allowing biotech companies to list without revenue, positioning Hong Kong as a key player in biotech investments.

What is a notable characteristic of the ETF discussed in the first section?

• It is primarily US-listed.

• It has a large market cap.

• It is highly volatile.

• It has a low expense ratio.

What analogy does Brad Loncar use to describe the Chinese biotech sector?

• The European tech boom of the 2000s

• The US biotech sector of the 80s and 90s

• The Japanese automotive industry of the 70s

• The Indian IT sector of the 90s

What is one reason the Chinese government supports the biotech sector?

• To reduce healthcare costs

• To increase tourism

• To develop a world-class biotech sector

• To compete with the US automotive industry

What has been a recent challenge for the immunotherapy sector?

• Lack of funding

• Disappointing clinical trial results for checkpoint combinations

• Regulatory hurdles in Europe

• Shortage of skilled researchers

What new rule in Hong Kong is benefiting biotech companies?

• Allowing biotech companies to list without earnings

• Reducing corporate tax rates

• Mandating local partnerships for foreign companies

• Providing government subsidies for research